Adjuvant immunotherapy improved DFS in patients with completely resected NSCLC, particularly those who were EGFR-negative, had PD-L1 levels of 1–49%, had non-squamous cell carcinoma, or never smoked. This evidence concerns the gene EGFR and non-small cell lung carcinoma.